Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information
Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter"). Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-17 4:19 PM EST | Elite Pharmaceuticals, Inc.
Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - February 17, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced continued progress in enrollment for its pivotal clinical trial of the investigational fully implanted Acclaim® cochlear implant. To date, 45 patients have been successfully implanted and are o
Biotechnology, Healthcare and Hospitals
2026-02-17 8:00 AM EST | Envoy Medical, Inc.
Theralase Bladder Cancer Clinical Data to be Presented at the 2026 European Association of Urology Congress
Toronto, Ontario--(Newsfile Corp. - February 17, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the 2026 European Association of Urology Cong
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-17 7:00 AM EST | Theralase Technologies Inc.
Adia Nutrition Announces Subsidiary Adia Med's Submission of Second Clinical Study for IRB Review Targeting Lower Back Pain with AdiaVita
Winter Park, Florida--(Newsfile Corp. - February 16, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and innovative therapeutic solutions, today announced that its subsidiary, Adia Med of Winter Park, LLC, has submitted its second clinical study for Institutional Review Board (IRB) review. This pivotal study will evaluate the efficacy of AdiaVita, Adia Med's proprietary umbilical cord blood-derived stem cell and exosome product, in alleviating lower back pain thro
Healthcare and Hospitals, Health
2026-02-16 9:00 AM EST | Adia Nutrition Inc.
Fonar Announces Financial Results for The 2nd Quarter of Fiscal 2026
Cash and cash equivalents decreased 6% to $53.0 million at December 31, 2025, as compared to $56.3 million for the fiscal year-ended June 30, 2025. Total Revenues - Net increased by 2% to $25.5 million for the quarter ended December 31, 2025, versus the corresponding quarter one year earlier. Total Revenues - Net increased by 3% to $51.6 million for the six-month period ended December 31, 2025, versus the corresponding six-month period one
Technology, Healthcare and Hospitals
2026-02-13 4:30 PM EST | Fonar Corporation
Envoy Medical Announces Closing of Up to $78.0 Million Upsized Public Offering
$30.0 million upfront with up to an additional $48.0 million of potential aggregate gross proceeds upon the exercise in full of milestone-linked warrants for cash Offering led by Nantahala Capital, with participation of healthcare-dedicated funds, including Broadfin Holdings, and participation from existing shareholder, Glen Taylor, and members of the Company's board of directors and management
Biotechnology, Healthcare and Hospitals
2026-02-12 4:05 PM EST | Envoy Medical, Inc.
HEALWELL AI Provides Corporate Update Highlighting Platform Integration Progress, Embedded AI Expansion and Continued Portfolio Simplification
HEALWELL has successfully integrated its Khure and Pentavere AI capabilities into a unified AI engine powered by DARWEN™ and is expanding its offerings across the joint customer base through coordinated Orion-Verosource commercial initiatives, enabling new upsell and cross-sell opportunities. HEALWELL is continuing to expand AI capabilities across its software platforms, including the North American launch of Amadeus AI in 1H-26, with international expansion planned for lat
Technology, Healthcare and Hospitals
2026-02-12 3:15 AM EST | HEALWELL AI
Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Ontario and Chicago, Illinois--(Newsfile Corp. - February 11, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2025 (the company's fiscal Q3 2026). All dollar amounts in this press release are in US dollars unless specified otherwise. Key update on GRAFAPEX Medexus has continued to see a positive market response to GR
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 5:30 PM EST | Medexus Pharmaceuticals Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026
Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company's financial and operating
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-11 4:30 PM EST | Elite Pharmaceuticals, Inc.
Envoy Medical Announces Pricing of Up to $78.0 Million Upsized Public Offering
White Bear Lake, Minnesota--(Newsfile Corp. - February 11, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the pricing of an upsized public offering of an aggregate of 75,000,000 shares of its Class A common stock (or pre-funded warrants in lieu thereof) accompanied by Series A-1 common warrants to purchase up to 45,000,000 shares of Class A common stock (or pre-funded wa
Biotechnology, Healthcare and Hospitals
2026-02-11 9:25 AM EST | Envoy Medical, Inc.
Theralase(R) Bladder Cancer Clinical Data to be Presented at the 2026 American Urological Association Annual Meeting
Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that its interim clinical data has been selected for presentation at the American Urological Asso
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-02-10 7:00 AM EST | Theralase Technologies Inc.
Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - February 10, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary IN
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-10 7:00 AM EST | Phio Pharmaceuticals Corp.
Conexeu Sciences Appoints Sonia Thomas as Head of Strategy & Transformation to Accelerate Enterprise Growth and Execution Excellence
Reno, Nevada--(Newsfile Corp. - February 9, 2026) - Conexeu Sciences Inc. ("Conexeu" or the "Company") a biotechnology innovator redefining regenerative medicine through a next-generation extracellular matrix platform, is pleased to announce Sonia Thomas, MBA, as Head of Strategy & Transformation. In her role, Sonia will help define Conexeu's enterprise strategy, shape portfolio priorities, and long-term growth decisions, and lead cross-functional transformation initiatives
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-09 9:00 AM EST | Conexeu Sciences Inc.
Adia Nutrition Inc. Plans to Initiate Four to Five New Clinical Studies in 2026, Including Expansions in Autism and New Rheumatoid Arthritis Research
Winter Park, Florida--(Newsfile Corp. - February 9, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026. These new initiatives will build on the company's ongoing success in regenerative therapies using Adia Vita (umbilical cord blood-derived stem cells and exosomes).
Healthcare and Hospitals, Health
2026-02-09 8:31 AM EST | Adia Nutrition Inc.
NuGen Medical Devices Inc. Provides Update on Health Canada License
Toronto, Ontario--(Newsfile Corp. - February 5, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is initiating a temporary halt on its devices in Canada due to the lapse of its license with Health Canada. The Company's Health Canada Licence became expired due to an untimely certificate renewal. This is not a suspension or cancellation related to regulatory compliance or enforcement action. The temporary status does not constitute a product safety
Healthcare and Hospitals, Pharmaceuticals, Health
2026-02-05 5:15 PM EST | NuGen Medical Devices Inc.
James Anderson Provides Update on Holdings of MyndTec Inc.
Detroit, Michigan--(Newsfile Corp. - February 5, 2026) - James Anderson (the "Investor") announces update to his ownership of common shares in the capital of MyndTec Inc. (the "Issuer") (the "Common Shares") and common share purchase warrants of the Issuer (the "Warrants"). On February 4, 2026, the Issuer completed an additional tranche (the "Current Tranche") of a private placement of units ("Units") announced on January 30, 2025. 650,970 Unit
Technology, Healthcare and Hospitals, Health
2026-02-05 4:52 PM EST | James Anderson
Discovery Senior Living CEO Richard Hutchinson Named Chair of American Seniors Housing Association
Bonita Springs, Florida--(Newsfile Corp. - February 5, 2026) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., is pleased to announce that its Chief Executive Officer, Richard Hutchinson, has been named Chair of the American Seniors Housing Association (ASHA), the nation's leading organization representing senior living owners, operators, developers, and
Healthcare and Hospitals, Real Estate, Housing
2026-02-05 2:28 PM EST | Discovery Senior Living
MyndTec Inc. Completes Additional Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - February 4, 2026) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed an additional tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The additional tranche of the private placement, the eleventh of the Offering, consists of 650,970 Units of the Company (the "
Technology, Healthcare and Hospitals, Health
2026-02-04 6:00 PM EST | MyndTec Inc.
Familywood Launches Canada's Leading Online Clinical Counselling Service for Families Affected by Addiction
Kelowna, British Columbia--(Newsfile Corp. - February 4, 2026) - Familywood proudly announces the launch of its online clinical counselling platform dedicated exclusively to supporting families impacted by addiction. Recognizing that addiction affects entire family systems, not only the individual in recovery, Familywood provides families with accessible, evidence-based therapy to help them heal, reconnect, and learn how to effectively support their loved one's recovery journey.
2026-02-04 4:14 PM EST | Familywood Family Support Services Inc.
Adia Nutrition Inc. Announces Effectiveness of Form 10 Registration Statement - Now a Fully Reporting SEC Company and Advancing Toward Next Phase of Growth and NASDAQ Uplisting
Winter Park, Florida--(Newsfile Corp. - February 4, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions through its Adia Med division, today announced that its Form 10 registration statement became effective on February 3, 2026, as anticipated and in accordance with the U.S. Securities and Exchange Commission's (SEC) prior notification. The Form 10, originally filed on December 5, 2025, was not subject to furt
Healthcare and Hospitals, Health
2026-02-04 9:32 AM EST | Adia Nutrition Inc.